Manage Your Liver
Q:

Why is the hepatitis C virus (HCV) so difficult to kill?

A:

The hepatitis C virus (HCV) infects millions of people worldwide. Patients are desperate for an effective treatment but medical professionals and the pharmaceutical industry have yet come up with the ideal one. There are two main reasons why HCV is so hard to kill.

 

First, HCV knocks out the host’s innate immunity. By constant mutation, HCV may be able to escape detection and elimination by the host’s immune system. [1] Therefore, it is almost impossible for the host to kill the virus without external help.

 

Second, HCV is highly mutable. HCV is an RNA virus and lacks proofreading ability as it replicates, therefore dozens of mutated forms arise. Even within an individual, slightly different genetic versions of HCV are present. According to WHO, there are at least 11 HCV genotypes identified throughout the world. The genotype is the strain of the virus to which patients were exposed when they were infected. [1]

 

The genotype generally does not affect the progression of liver diseases. However, it is of great clinical importance; different genotypes vary in their responsiveness to HCV treatments. For example, compared with genotype 1, patients with genotypes 2 and 3 are more likely to achieve a sustained virological response to interferon/ribavirin therapy. In addition, therapy duration also varies among different genotypes. Patients with genotypes 2 or 3 generally are treated with combination therapy for only 24 weeks, while patients with genotype 1 usually receive treatment for 48 weeks. [2]

 

Traditionally, combination therapy with interferon/ribavirin is recommended for HCV patients. Interferons do not directly kill the virus; instead they boost the immune system response to attack the virus. The success rate for such therapy is very low and often comes with unbearable side effects such as fever, headache and other flu-like symptoms. [3]

 

In recent years, new medications for HCV were developed. One of the most promising is Harvoni, a direct-acting antiviral (DAA) medication. Unlike interferon, DAAs directly inhibit the ability of HCV to replicate. Harvoni is a combination of two DAAs where one interferes with the reproduction of the virus’s genetic material, while the other interferes with a protein needed to complete the virus life cycle in the liver cell.

 

Although Harvoni claims to have high success rates in clinical studies, not many patients can afford it due to its extremely high cost. Moreover, a person could get infected again even after successful treatment. [4]

 

Despite the introduction of new drugs, treatment options for hepatitis C patients are still limited. If patients are unable to receive antiviral treatment due to genotype or financial reasons, or have tried and failed, they should shift their treatment focus to protecting liver function and reducing inflammation (ALT).

Disclaimer:
  • * All research and clinical data should be used as reference purposes only, results may vary.
Tags:
Hepatitis CHep CHCVChronic Hepatitis CHarvoniInterferonRibavirin
Related Questions
A:
In our last post, we brought up the recent findings on extreme liver cancer growth after successful DAA treatment. We are talking about liver cancer of a few centimetres developed within weeks of successful Hep C treatment. These findings are also observed in patients of Gastroenterology. Dr. Roushdi Khalf allah sai
A:
You probably have already heard about the new antiviral hep C drug, which is effective but insanely expensive. It claims to have around 90% success rate, that’s why so many hepatitis C patients are dying for it even though it’s extremely costly. But apart from its expensive price tag, there is a bigger issue behind this new drug that not many people know about. Scientists and researchers have found an increased risk of extreme liver cancer related to this new drug after successful
Hit Questions
A:
Research and developing our products has always been a big part of our work. Kyotsujigyo has worked with a number of well established organisations and universities in the past, including the University of Sao Paulo, GAIA Age-Management Foundation, The University of Western Ontario, University of Virginia, Yanaihara Research Institute,  Harada Hospital (Japan) and others.    In 2016 Kyotsujigyo has corporate with the National Key Research Institute in Hong K
A:
NASH is inflammation in the liver developed from accumulated fat in the organ, also known as fatty liver. NASH damages liver cells and liver function, which results in elevated ALT liver enzyme level.    As there are no approved treatments for NASH, the standard recommendation for patients is to lose weight only. However this doesn’t work for everyone so if you are struggling to find a way to stop NASH, please read on.   Wha
A:
In 2010, some 4.7 million people aged 65 years or older lived with Alzheimer's disease in the US.   Alzheimer’s is a common brain disease that causes progressive brain cell death that happens over a course of time. It will also cause a shrink in brain size as the tissue has progressively fewer nerve cells and connections. Alzheimer’s is thought to be caused by Protein Plaques building up in the brain cells, these Plaques are found between the dying cel
A:
There are between 10 to 15 million patients in the U.S. with NASH, and among these patients, one-fifth to one-fourth are at risk for cirrhosis or chronic liver damage.   The major characteristic of NASH is fat in the liver, along with inflammation and damage. NASH can be severe and can lead to cirrhosis. The number of NASH cirrhosis patients is currently on the rise, and it is predicted (NAFLD & NASH) to be the number 1 cause of liver transplants by 2020. [1] Ther
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Have Questions?
Sumbit your question to us for profeessional answers!
Have
Questions?
Sumbit your question
to us for profeessional answers!
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Looking for help? Ask our customer support team!
Contact Us